Boundless Bio Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Boundless Bio Inc
Access all reports
Boundless Bio Inc., trading under the NASDAQ symbol BOLD, is a clinical-stage oncology company focused on developing novel cancer treatments. The company leverages its proprietary Spyglass platform to target extrachromosomal DNA (ecDNA), which plays a significant role in oncogene amplification in over 14% of cancer patients. By identifying and inhibiting targets essential for ecDNA functionality, Boundless Bio aims to develop ecDNA-directed therapeutic candidates (ecDTx) designed to selectively eliminate cancer cells containing ecDNA without harming healthy cells. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Latest articles
)
Figma: Collaborative Design Tool Ready for IPO
Figma, the popular design platform, is preparing for a potential IPO in 2025 as it continues to reshape the future of collaborative design.
22 May 2025
)
Companies That Had Their IPO in 2024: Momentum Increasing
2024 marked a steady year for IPOs, driven by strong markets, AI momentum, and high-profile listings across industries and regions.
22 May 2025
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
Ticker symbol
BOLD
Country
🇺🇸 United States